LAX.SH
AAREY DRUGS & PHARM LTD·Healthcare Companies·Pharmaceuticals & Biotechnology Companies
Price
81.2
+0.75%52W Range
Market Cap
₹230.24 Cr
Traded: ₹5.60 Cr (2.43%) 0.0x
Free Float: ₹109.66 Cr (5.11% of FF traded)
Volume · 60D trend
6.99 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
29 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | +5.0% | +4.0% | +3.0% | -- | -- | Decelerating |
| Return | +7.0% | +16.0% | +22.0% | +27.0% | -- | Accelerating |
| Profit | +12.0% | -9.0% | +2.0% | -- | +0.0% | Stable |
| Sales | +7.0% | +6.0% | +4.0% | -- | -8.0% | Decelerating |
Quarterly Results
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 45 | 189 | 96 | 84 | 102 | 108 | 134 | 105 | 127 | 210 | 76 | 58 | 51 | 163 |
| Expenses | 43 | 185 | 98 | 82 | 101 | 112 | 132 | 101 | 126 | 212 | 74 | 56 | 50 | 160 |
| Operating Profit | 1 | 4 | -2 | 3 | 2 | -4 | 2 | 4 | 1 | -1 | 3 | 2 | 1 | 3 |
| OPM % | 3.0% | 2.3% | -1.6% | 3.1% | 1.7% | -3.9% | 1.6% | 3.5% | 0.9% | -0.7% | 3.5% | 3.2% | 2.6% | 1.6% |
| Other Income | 2 | -0 | 4 | 1 | 2 | 8 | 1 | 0 | 2 | 5 | 0 | 1 | 1 | 1 |
| Interest | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 2 | 0 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 2 | 1 | 2 | 1 | 1 | 1 | 2 |
| Tax % | -98.1% | -21.9% | 38.0% | 31.1% | 20.8% | 71.6% | 48.6% | 8.6% | 6.8% | -0.5% | 30.1% | -22.0% | 0.0% | 83.2% |
| Net Profit | 1 | 2 | 1 | 1 | 1 | 0 | 1 | 2 | 1 | 2 | 1 | 1 | 1 | 0 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 0.4 | 0.6 | 0.2 | 0.4 | 0.5 | 0.2 | 0.3 | 0.6 | 0.4 | 0.8 | 0.4 | 0.5 | 0.3 | 0.1 |
| Sales Growth (YoY) | -56.3% | 75.3% | -27.9% | -19.9% | -19.5% | -48.6% | 74.9% | 81.8% | 149.0% | 29.1% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -76.4% | 96.5% | 14.6% | -17.7% | -5.5% | -19.2% | 27.3% | -17.1% | -39.7% | 175.0% | 32.3% | 13.5% | -68.7% | -- |
| OP Growth (YoY) | -22.8% | 203.1% | -168.6% | -29.0% | 44.9% | -192.4% | -18.5% | 102.2% | -11.9% | -157.1% | -- | -- | -- | -- |
| OP Growth (QoQ) | -69.6% | 387.4% | -157.2% | 54.4% | 140.6% | -291.4% | -40.9% | 215.3% | 181.9% | -153.3% | 46.7% | 37.3% | -46.8% | -- |
| Profit Growth (YoY) | -25.6% | 231.9% | -20.8% | -36.3% | 10.5% | -78.1% | -29.4% | 30.1% | 72.2% | 497.2% | 2.0% | -42.0% | -10.0% | 147.0% |
| EPS Growth (YoY) | -25.0% | 223.5% | -20.0% | -36.8% | 9.1% | -77.9% | -37.5% | 18.8% | 57.1% | 450.0% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -34.5% | 175.0% | -44.4% | -25.0% | 182.3% | -32.0% | -56.1% | 29.6% | -42.9% | 92.5% | -16.7% | 71.4% | 100.0% | -- |
| OP Margin | 3.0% | 2.3% | -1.6% | 3.1% | 1.7% | -3.9% | 1.6% | 3.5% | 0.9% | -0.7% | 3.5% | 3.2% | 2.6% | 1.6% |
| Net Margin | 2.3% | 0.8% | 0.6% | 1.2% | 1.3% | 0.4% | 0.5% | 1.5% | 1.0% | 1.0% | 1.3% | 2.1% | 1.4% | 0.2% |
| Material Cost % | 94.0% | 95.0% | 100.0% | 96.0% | 96.0% | 101.0% | 97.0% | 94.0% | 97.0% | 98.0% | 95.0% | 95.0% | 94.0% | 97.0% |
| Employee Cost % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| P/S | 0.56 | 0.50 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 55.24 | 52.75 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 1.53 | 1.59 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50As per the attachment
As per Attachment
Outcome of Board Meeting held on friday, 14th August, 2026
Aarey Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve This is to intimate ....
Allotment of Equity Shares Pursuant to Conversion of Warrants
Compliance Certificate under Reg 74(5) of Sebi(DP) Regulation 2018
Intimation for closure of trading window
As per Attachment
Outcome of Board Meeting held on Saturday, 30th May, 2026
As per Attachment
As per attachment
as per attachment
Aarey Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve intimation regarding ....
Aarey Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve Pursuant to the ....
Certificate under Reg 74(5) of SEBI (Depositories and Participants) Regulations, 2018
Intimation for closure of trading window
Newspaper Publication of the Unaudited Financial Results
Board Comments on the fine levied by the Exchange
Approval of Unaudited Financial Results for the quarter ended 31st December, 2025
This is to inform you that the Board of Directors of the Company at its Meeting held today i.e. 11th February, 2026 have passed the following resolution. 1. The Board of Directors of the ....
Aarey Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 ,inter alia, to consider and approve This is to intimate ....
Certificate under reg 74(5) of SEBI (Depositories and Participants) Regulations, 2018
Intimation for Closure of Trading Window
Newspaper Publication of the Unaudited Financial Results
Approval of Unaudited Financial results for the quarter & half year ended on 30th Sept 2025
Outcome of Board meeting for approval of Unaudited Financial Results for the quarter and half year ended 30th September, 2025
Aarey Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 ,inter alia, to consider and approve This is to intimate ....
Certificate under regulation 74(5) of SEBI (Depository and Participants) Regulations, 2018 for the quarter and half year ended 30th September, 2025
Disclosure on Voting Results along with Consolidated Scrutinizers Report of 35th Annual General Meeting of the Company
Closure of Trading Window for the Quarter and half year ended 30 September, 2025
AGM Proceedings of the 35th Annual General Meeting of the Company
Corrigendum to the integrated Annual Report for FY 2024-25
Newspaper Publication
Notice and Integrated Annual Report for 35th Annual General Meeting of Company as required under Regulation 34(1)
Notice of 35th Annual General Meeting of the company for the financial year 2024-25
INTIMATION OF BOOK CLOSURE
With reference to the Outcome submitted yesterday i.e., on 03.09.2025 we would like to clarify that due to inadvertent error in Point No. 2 of the Outcome, the time of the Annual General ....
Please find enclosed Disclosure
Pursuant to Regulation 30 (read with Part A of Schedule 1ll) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), ....
Newspaper Publication
Unaudited Financial Results for the quarter ended 30th June, 2025 along with the Limited Review Report, MD/CFO Certificate
Outcome of Board Meeting held on today i.e 13th August, 2025
Aarey Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2025 ,inter alia, to consider and approve This is to intimate ....
Revised filing of Audited Financial Results for the year ended 31st March, 2025
Certificate under Regulation 74(5) of SEBI (Depositories And Participants) Regulations, 2018 for the quarter ended 30th June, 2025
Intimation for Closure of Trading Window for Quarter Ended June 2025.
Submission of Newspaper copies of publication of Audited Financial Results of the company for the quarter and year ended on 31st March 2025
Audited Financial Result For the year ended on 31st March 2025
This is to inform you that the Board of Directors of the Company at its Meeting held today i.e. 30th May, 2025 have passed the following resolution. 1. The Board of Directors of the Company ....
Annual secretarial Compliance Report for the year ended on 31st March 2025
Annual Reports
15